Dimethyltryptamine: Endogenous Role and Therapeutic Potential
Alexandra Vsl Rodrigues, Francisco Almeida, Maria Augusta Vieira‐coelho
Journal of Psychoactive Drugs April 25, 2019 DOI: 10.1080/02791072.2019.1602291 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Humans |
| Topics | Anxiety Ayahuasca 5-MeO-DMT DMT |
| Keywords | Hallucinogen Depression economics Pharmacology |
| Citations | 30 |
| Key findings | Ayahuasca shows promising results for anxiety, depression, and substance dependence, though the role of endogenous DMT remains unclear. |
Abstract
N, N-dimethyltryptamine (DMT) is an indole alkaloid produced by a number of plants and animals, including humans. Its psychoactive effects were first described in 1956 by Stephen Szára, but have been exploited for centuries by South American indigenous populations in the form of ayahuasca. In the present review, we assess the state of the art regarding a putative role for endogenous DMT and potential clinical applications of ayahuasca and DMT. A review assessing the pharmacological profile of DMT and its clinical effects in humans was performed using the PubMed data base until 5 August 2018 with the words: ayahuasca and N,N-dimethyltryptamine. While the role of endogenous DMT remains unclear, ayahuasca has promising results in anxiety, depression and substance dependence. Since ayahuasca has a good safety profile, it is crucial to conduct further research aimed at developing new treatments for psychiatric disorders.
Comparable studies
Other narrative reviews on ayahuasca for anxiety, most cited first.
Citations in the library
Cited by 25
- Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT Psychopharmacology January 22, 2022
- Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm Australian & New Zealand Journal of Psychiatry March 21, 2021
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine Human Psychopharmacology: Clinical and Experimental February 17, 2022
- An Encounter With the Other: A Thematic and Content Analysis of DMT Experiences From a Naturalistic Field Study Frontiers in Psychology December 16, 2021
and 20 more in the library
Cites 68
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor Molecular Pharmacology December 1, 2001
- The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator Science February 13, 2009
and 63 more in the library